Back to search

University of Glasgow

Targeted protein degradation of the Y220C-p53 mutant as a potential anti-cancer strategy

Abstract

dc:description.abstract

Targeted protein degradation and Proteolysis Targeting Chimeras (PROTACs) in particular, have become an exciting new field in the drug discovery world, with the potential to target previously seen as ‘undruggable’ proteins. With many PROTACs now reaching the clinic, it is clear that these new modalities have the potential to become therapeutically successful and to overcome problems previously observed with traditional small molecule drugs. One of the most frequently mutated proteins in human cancers, p53 has been a particularly challenging drug target for many years. The work presented in this thesis provides a strategy in which to target and degrade the common Y220C p53 mutant by utilising the PROTAC degradation mechanism. In particular, PROTAC 2 was found to degrade the Y220C p53 mutant at a low micromolar concentration and hence provides insight into the potential these PROTACs hold for the future as potent degraders of target proteins.

Degree

thesis:*
Level dc:type.qualificationlevel
MRes
Grantor dc:publisher.institution
University of Glasgow
Year dc:date.issued
2024

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • Miller, Hollie

Subjects

dc:subject × 2

Rights

Language dc:language
en

Identifiers

dc:identifier.*

Chain of custody

source
Harvested from
University of Glasgow
Base URL
theses.gla.ac.uk/cgi/oai2
Last updated
2026-11-19
Source record
OAI-PMH GetRecord
citation

Miller, Hollie. Targeted protein degradation of the Y220C-p53 mutant as a potential anti-cancer strategy. MRes thesis, University of Glasgow, 2024. https://doi.org/10.5525/gla.thesis.84041